Key highlights include:

 • 📊 Screening trends: How PSA guidelines have swung over time, the risks of over- and under-diagnosis, and why smarter screening is critical.

 • ⚖️ Risk stratification: Understanding the spectrum from indolent “snails” to aggressive “rabbits,” and how tools like the CAPRA score improve decision-making beyond traditional NCCN categories.

 • 👀 Active surveillance: Why surveillance—not immediate treatment—is the standard of care for most low-risk cancers, and how MRI, confirmatory biopsies, and genomic tests refine monitoring.

 • 🔬 Focal therapy: The promise and limits of approaches like HIFU, cryotherapy, and laser ablation, and why they should be viewed as complements to surveillance rather than replacements for surgery or radiation.

 • 🧪 Genomic and AI testing: Where tools like Decipher, Polaris, and emerging pathology AI fit in—and where they don’t—when guiding patient choices.

 • 🏥 Second opinions & centers of excellence: Why outcomes vary widely, and the importance of seeking subspecialist expertise before choosing a treatment path.

Dr. Cooperberg also emphasizes the urgent need to reduce racial disparities, personalize treatment decisions, and support men living with prostate cancer long after initial therapy.